To customize how your Tropy item is mapped to CSL/JSON and Zotero, duplicate your Tropy template in Tropy's template editor and assign each field you want to export a CSL/JSON field by setting the ...

CSL’s share slump following weak profits and a sudden CEO exit has pulled Australian healthcare stocks to multi-year lows, highlighting sector-wide concerns over regulation and investor sentiment. CSL ...

CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

CSL’s interim chief executive Gordon Naylor has pleaded with angry investors for more time to return the global healthcare giant to its former glory, saying he will look at selling or scaling back non ...

Australian pharmaceuticals heavyweight CSL has announced its chief executive Dr Paul McKenzie is retiring with immediate effect, as the company tries to rebuild confidence among investors following a ...

For the best part of a decade, the company was unimpeachable. But the sudden exit of chief executive Paul McKenzie underscores the new sense of chaos around the group. It’s all just so out of ...

The news: Embattled biotech giant CSL has announced the retirement of CEO and managing director Paul McKenzie, effective today. CSL senior executive and non-executive director Gordon Naylor has been ...

Good afternoon, everyone, and thank you for joining us on short notice. My name is Mark Dehring, Head of Investor Relations at CSL. The focus of today's call is CSL's leadership transition, and we ...

With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the eve of its latest earnings announcement. Paul McKenzie, Ph.D., who’s served ...

CSL taps ex-vaccine division head Gordon Naylor as interim CEO Appointment of Naylor is a salvage mission, says analyst CSL shares close 5% lower; co to report HY results on Wed Feb 10 (Reuters) - ...

CSL has gotten the Memo about the value of recombinant polyclonal immunoglobulin (IgG) antibodies. The company is signing on to a collaboration and option agreement with Memo Therapeutics that could ...

Building envelope solutions provider Carlisle Companies (NYSE:CSL) will be reporting earnings this Tuesday after market close. Here’s what investors should know. Carlisle beat analysts’ revenue ...